ReviewBiomedicines2023
The Role of the Ectopeptidase APN/CD13 in Cancer.
Review in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- CRISPR/Cas9 loss-of-function screen in a neuronal model of AP-4 deficiency identifies ATG9A trafficking modulators.JCI insight · 2026Article
- Improving a Plasma Biomarker Panel for Early Detection of Pancreatic Ductal Adenocarcinoma with Aminopeptidase N (ANPEP) and Polymeric Immunoglobulin Receptor (PIGR).Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Aminopeptidase N: the glucocorticoid gateway linking chronic stress to ferroptosis resistance in liver cancer.The Journal of clinical investigation · 2026Article
- Molecular insights into ANPEP in gastric adenocarcinoma.Genetics and molecular biology · 2026Article
- New Therapeutic Options Against Clinically Relevant Proteases in Cancer Progression.Mini reviews in medicinal chemistry · 2026Review
- Downregulation of ANPEP Is Associated with Aggressive Prostate Cancer and Poor Disease-specific Outcomes.European urology open science · 2026Article
- Expression Characteristics of Soluble sCD13 in Wet Age-Related Macular Degeneration and Its Diagnostic Value and Correlation Study.International journal of general medicine · 2026Article
- Alpha- and Beta-Coronaviruses in Humans and Animals: Taxonomy, Reservoirs, Hosts, and Interspecies Transmission.Microorganisms · 2025Review
- Bioinformatic Approach to Identify PotentialInternational journal of molecular sciences · 2025Article
- Identification of novel biomarkers involved in oral squamous cell carcinoma by whole transcriptome sequencing and bioinformatics analysis.Cancer cell international · 2025Article
- Unveiling Cancer-Related Metaplastic Cells in Both Helicobacter pylori Infection and Autoimmune Gastritis.Gastroenterology · 2025Article
- Article
- Integrin Targeting and Beyond: Enhancing Cancer Treatment with Dual-Targeting RGD (Arginine-Glycine-Aspartate) Strategies.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Phenotype remodelling of HNSCC cells in the muscle invasion environment.Journal of translational medicine · 2024Article
- Cyanine dyes in the mitochondria-targeting photodynamic and photothermal therapy.Communications chemistry · 2024Review
- CD13 expression affects glioma patient survival and influences key functions of human glioblastoma cell lines in vitro.BMC cancer · 2024Article
- The DNA repair kinase ATM regulates CD13 expression and cell migration.Frontiers in cell and developmental biology · 2024Article
- Article
- The intricate interplay between cancer stem cells and cell-of-origin of cancer: implications for therapeutic strategies.Frontiers in oncology · 2024Review
- NGR-Based Radiopharmaceuticals for Angiogenesis Imaging: A Preclinical Review.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
APN/CD13 is expressed in a variety of cells/tissues and is therefore associated with diverse physiological functions, including proliferation, differentiation, migration, angiogenesis, invasion, metastasis, vasoconstriction, and the regulation of normal and impaired immune function. Increased expression or activity of APN/CD13 has been described for various tumors, such that APN/CD13 is in most cases associated with reduced disease-free and overall survival. The mechanisms that mediate these cellular effects of APN/CD13 have been largely determined and are described here. APN/CD13-regulated signaling pathways include integrin recycling, the regulation of small GTPase activities, cell-ECM interactions, and Erk1/2, PI3K, and Wnt signaling. APN/CD13 is a neo-angiogenesis marker that is not found on normal endothelia, but it is found on neo-angiogenetically active endothelia. Therefore, APN/CD13 represents a specific receptor for so-called "tumor-homing peptides" (NRG peptides). Peptides containing the NRG motif show high-affinity binding to APN/CD13. APN/CD13 thus represents a versatile target for the inhibition of tumor-induced angiogenesis through the tumor-selective administration of, e.g., cytotoxic substances. Furthermore, it enables the molecular imaging of tumor masses and the assessment of (neo)angiogenesis in animal models and in patients. Pharmacological inhibitors of APN/CD13 have been proven to reduce tumor growth and tumor progression in various APN/CD13-positive tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.